US03168L1052
US03168L1052
Amneal Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 3.018.760.000 | 2.793.957.000 | 8.0% |
| Cost of Revenue | 1.905.452.000 | 1.773.519.000 | 7.4% |
| Gross Profit | 1.113.308.000 | 1.020.438.000 | 9.1% |
| 715.394.000 | 672.065.000 | 6.4% | |
| Operating Income | 397.914.000 | 348.373.000 | 14.2% |
| Pretax Income | 139.209.000 | -55.013.000 | 353.0% |
| Net Income Common Stockholders | 72.057.000 | -116.886.000 | 161.6% |
| -- | -- | -- | |
| -- | -- | -- |